Bioscience Entrepreneurship and Entrepreneurship in Life Science are the key tracks for the reformed GIBBS, the bioscience entrepreneurship education founded in 2005. The key aspects of educating and motivating future entrepreneurs in the corresponding fields of biotechnology and biomedicine are emphasized in the respective tracks at Chalmers and the Sahlgrenska Academy. GIBBS thus takes a strong collaboration to a new level between the two universities while also relying on cross-boundary co-operation with industrial partners such as AstraZeneca within GöteborgBIO.
Since the start GIBBS has been educating future entrepreneurs into Masters of Science, adding on the Masters of Medical Science, while developing innovative ideas into companies. With focus on bioscience and biomedicine, students gained access to the networks necessary to develop ideas into commercial reality. Since 2012, GIBBS is manifested as two separate educational tracks within the entrepreneurship educations at Chalmers and the Sahlgrenska Academy.
“The stronger integration with each university is a result of our ambition to bring the entrepreneurial activities closer to the academic environments, while at the same time maintaining the important connections to our industrial partners”, Director Boo Edgar explains.
Shared vision of realising potential of innovations
To be able to differentiate and profile the programs even more in relation to the characteristics of its parent universities, there is now a Bioscience track integrated into Chalmers School of Entrepreneurship. At the University of Gothenburg, GIBBS constitutes an Entrepreneurship in Life Science track within the master program Business Creation and Entrepreneurship in Biomedicine.
However, it is important to note that GIBBS as a project for realising potential of innovations to become full-scale commercial projects is managed in the same way at both universities. Both Chalmers and University of Gothenburg therefore manage industrial co-operation.
Taking projects further
GIBBS offers carefully crafted learning and innovation activities to its students and partners. Mats Lundqvist, co-founder of GIBBS, underlines the importance of bringing good ideas forward and making them commercially viable through the education.
“We have the knowledge and experience required to realise complex projects based on innovations originating from our own universities as well as external environments. We meet researchers every day; they form the foundation with the bearing idea on which we can build commercial value. What we offer is know-how on what is important in order to reach the goal of full commercialisation. We have the necessary contacts, we have long-term commitments from companies such as AstraZeneca, and we are thus able to bring the projects on to a higher level”.
From artificial blood vessels to cancer-treatments
Needless to say, there are several good examples of successful projects originating from the GIBBS environment. The forward-striving bio-medical company Arterion is a perfect example where knowledge from both Chalmers and the University of Gothenburg has been combined with expertise originating from the Sahlgrenska University Hospital (SU). Arterion manufactures biomaterials, including artificial blood vessels for revascularisation of patients with cardiovascular diseases.
Another example is from this year’s regions final in Venture Cup, where the third prize in the business plan competition was rewarded to students from GIBBS. The students behind the project Velit Biologics have developed a new cancer treatment called SB101 in collaboration with researchers from Estonia. Velit Biologics was rewarded with 50 000 SEK.
“Our strength lies in our ability to combine expertise from different fields. Both Arterion and Velit Biologics are excellent examples of this. We have several other interesting and prosperous projects that we believe in. Some originated from external environments, but have accelerated with our help. This is what we offer – the motivation and strength to bring out the best in each bio-scientific project, thereby bringing it closer to the commercial market”, Boo Edgar concludes.